AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Liver and Coagulation Disorders in Cardiac Transthyretin Amyloidosis

Recruitingn/aAges 18 Years - anyAllUniversity of Messina
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Transthyretin cardiac amyloidosis (ATTR-CA) is a progressive infiltrative cardiomyopathy caused by the deposition of misfolded transthyretin protein within the myocardium. Current disease staging and follow-up strategies mainly rely on cardiac biomarkers and renal function; however, the systemic nature of ATTR suggests that additional organ involvement may provide valuable prognostic information. The purpose of this prospective observational study is to investigate liver dysfunction and coagulation abnormalities in patients with wild-type or hereditary ATTR-CA and to evaluate their potential role as novel markers of disease severity and progression. Patients with ATTR-CA will be compared with an age-matched control population with non-amyloid hypertrophic cardiomyopathy. Clinical, laboratory, echocardiographic, hepatic ultrasound, liver stiffness, and coagulation parameters will be ass

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Written informed consent obtained prior to study participation. * Diagnosis of wild-type or hereditary transthyretin cardiac amyloidosis (ATTR-CA) according to current European recommendations. * Ability to comply with study procedures and follow-up visits. Exclusion Criteria: * Age younger than 18 years. * Severe liver dysfunction due to causes other than amyloidosis. * Inability to comply with study procedures because of language barriers, cognitive impairment, or severe psychiatric disorders. * Comorbidities associated with life expectancy less than 12 months. * Active alcohol or substance abuse. * For coagulation analyses: congenital coagulation disorders, thrombotic disorders, active malignancy, or sepsis. * Pregnancy or breastfeeding.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
AOU Policlinico G. Martino, UOC Cardiologia con UTIC
Messina, Italy
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy